Serbin M, Mansfield C, Leach CA, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Do patients' experiences with side effects affect their preferences for adjunctive Parkinson's disease treatments? Poster presented at the 8th European Academy of Neurology Congress; June 25, 2022. Vienna, Austria. [abstract] Eur J Neurol. 2022 Jun; 29(Suppl 1):446.
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-76. doi: 10.1093/rheumatology/kex071
Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A. Patient's preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2017 Jan;56(1):68-76. doi: 10.1093/rheumatology/kew328
Xu J, Evans J, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience. 2013;7:351. doi: 10.3332/ecancer.2013.351.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Poster presented at the American College of Rheumatology 2007 Annual Scientific Meeting; April 2007. Chicago, IL. [abstract] Rheumatology (Oxford). 2007; 46:162-3.